Literature DB >> 8144950

Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes.

J Sandhu1, B Shpitz, S Gallinger, N Hozumi.   

Abstract

Severe combined immune deficient (SCID) mice were engrafted with human peripheral blood lymphocytes (Hu-PBLs) after treatment with anti-asialo GM-1 antiserum and radiation. This pretreatment facilitates high level of Hu-PBL engraftment in the SCID mice spleen. The next day, the Hu-PBL-SCID mice were immunized with either keyhole limpet hemocyanin (KLH), or carbohydrate Ag STn (AcNeu-alpha 2-alpha 6-Gal NAc-0) conjugated to KLH or protein of circumsporozoite malaria parasite (CSP), in a mixture of complete and incomplete Freund's adjuvant (1:10 v/v). The mice were bled 14 to 16 days after immunization, and the sera analyzed for STn-, KLH-, and CSP-specific human IgG and IgM Abs. The results showed that the immunized animals had a significantly higher titer of Ag-specific human IgG and IgM Abs compared to the control Hu-PBL-SCID mice. No significant Ab cross-reactions were detected between sera from KLH-, STn-, and CSP-vaccinated Hu-PBL-SCID mice. Depletion of either human CD4+ or CD8+ cells, in Hu-PBL-SCID mice, showed that CD4+ cells were essential for the primary immune response, but depletion of CD8+ cells had no influence on the titer of Ag-specific human IgG and IgM Abs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144950

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Authors:  G M Bahr; E C Darcissac; N Castéran; C Amiel; C Cocude; M J Truong; J Dewulf; A Capron; Y Mouton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection.

Authors:  Y T Teng; H Nguyen; X Gao; Y Y Kong; R M Gorczynski; B Singh; R P Ellen; J M Penninger
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 3.  SCID mice and the study of parasitic disease.

Authors:  K B Seydel; S L Stanley
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

4.  Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.

Authors:  L Covassin; J Laning; R Abdi; D L Langevin; N E Phillips; L D Shultz; M A Brehm
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

5.  Tetanus toxoid-specific T cell responses in severe combined immunodeficiency (SCID) mice reconstituted with human peripheral blood lymphocytes.

Authors:  R Somasundaram; L Jacob; D Herlyn
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

6.  A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.

Authors:  B Hardy; R Kovjazin; A Raiter; N Ganor; A Novogrodsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

7.  Antigen-specific B and T cells in human/mouse radiation chimera following immunization in vivo.

Authors:  W O Böcher; H Marcus; R Shakarchy; B Dekel; D Shouval; E Galun; Y Reisner
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

8.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

9.  Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system.

Authors:  R Eren; I Lubin; D Terkieltaub; O Ben-Moshe; A Zauberman; R Uhlmann; T Tzahor; S Moss; E Ilan; D Shouval; E Galun; N Daudi; H Marcus; Y Reisner; S Dagan
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

10.  In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine.

Authors:  Wang Junwei; Zhan Xiumin; Ye Jing; Yang Shoujing; Li Zengshan
Journal:  Cancer Cell Int       Date:  2016-06-17       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.